Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma

Published:November 24, 2022DOI:



      To assess clinical outcomes of patients who underwent simultaneous radical cystectomy (RC) and radical nephroureterectomy (RNU) for panurothelial carcinoma (PanUC).

      Materials and Methods

      A retrospective analysis of 67 patients who underwent simultaneous RC and unilateral RNU for PanUC, from 1996 to 2017. Kaplan-Meier estimates for remnant urothelium recurrence-free survival, metastasis-free survival, overall survival (OS), and cancer-specific survival (CSS) were performed. Cox multivariate models were constructed.


      The median follow-up was 38 months, 29.8% of patients had a recurrence, 34.3% had metastasis, 67.2% of patients died from any cause, and 37.3% died from urothelial carcinoma. Overall survival and CSS rates at 5 years were 44% and 61%, respectively. In multivariate analysis, progression to muscle-invasive bladder cancer before surgery, presence of muscle-invasive stages at RC and/or RNU, and prostatic urethra involvement were predictors for worse metastasis-free survival and CSS. Forty-one patients (61.2%) had an estimated glomerular filtration rate (eGFR) <60 mL/min before surgery and the number rose to 56 (83.5%) after surgery; 29.8% patients needed renal function replacement therapy after surgery (16 haemodialysis and 4 renal transplant).


      Patients with PanUC who undergo simultaneous surgery have adverse oncological (only 4 out of every 10 remain alive at 5 years) and functional outcomes (1 out of 3 will need renal function replacement therapy after surgery). Up to a third of the patients had a recurrence (urethra or contralateral kidney) within 18 months, justifying close surveillance or considering prophylactic urethrectomy. These data should help in counsel on morbidity and life expectancy.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Solsona E
        • Iborra I
        • Ricos JV
        • Monros JL
        • Rubio J
        • Almenar S.
        Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
        J Urol. 2002; 167: 2007-2011
        • Gakis G
        • Black PC
        • Bochner BH
        • et al.
        Systematic review on the fate of the remnant urothelium after radical cystectomy.
        Eur Urol. 2017; 71: 545-557
        • Li Q
        • Assel M
        • Benfante N
        • et al.
        Clinical outcomes in patients with panurothelial carcinoma treated with radical nephroureterectomy following cystectomy for metachronous recurrence.
        J Urol. 2017; 198: 546-551
        • Picozzi S
        • Ricci C
        • Gaeta M
        • et al.
        Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients.
        J Urol. 2012; 188: 2046-2054
        • Babjuk M
        • Burger M
        • Capoun O
        • et al.
        European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ).
        Eur Urol. 2022; 81: 75-94
        • Roupret M
        • Babjuk M
        • Burger M
        • et al.
        European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update.
        Eur Urol. 2021; 79: 62-79
        • Witjes JA
        • Bruins HM
        • Cathomas R
        • et al.
        European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 Guidelines.
        Eur Urol. 2021; 79: 82-104
        • Aumatell J
        • Huguet J
        • Subiela JD
        • et al.
        Endoscopic exploration directly impacts clinical decision making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomy.
        Urol Oncol. 2021; 39: 732 e1- e8
        • Fang D
        • Liu P
        • Li X
        • et al.
        Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients.
        Sci Rep. 2015; 5: 18014
        • von Elm E
        • Altman DG
        • Egger M
        • et al.
        The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies.
        Int J Surg. 2014; 12: 1495-1499
        • Fahmy O
        • Khairul-Asri MG
        • Schubert T
        • et al.
        Urethral recurrence after radical cystectomy for urothelial carcinoma: a systematic review and meta-analysis.
        Urol Oncol. 2018; 36: 54-59
        • Khanna A
        • Zganjar A
        • Lyon T
        A contemporary analysis of urethral recurrence following radical cystectomy.
        J Urol. 2021; 206: 970-977
        • Huguet J.
        [Diagnosis and treatment of urethral recurrence after radical cystectomy in the male].
        Actas Urol Esp. 2012; 36: 42-47
        • Hakozaki K
        • Kikuchi E
        • Ogihara K
        • et al.
        Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer.
        Jpn J Clin Oncol. 2021; 51: 287-295
        • Carpinito GP
        • Cook GS
        • Tverye AN
        • et al.
        Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: a single-institution series.
        Can Urol Assoc J. 2022; 16: E363-E3E9
        • Rodriguez Faba O
        • Palou J
        • Breda A
        • et al.
        Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma.
        Urol Int. 2014; 92: 169-173
        • Vejlgaard M
        • Maibom SL
        • Stroomberg HV
        • et al.
        Long-term renal function following radical cystectomy for bladder cancer.
        Urology. 2022; 160: 147-153
        • Madersbacher S
        • Hochreiter W
        • Burkhard F
        • et al.
        Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy.
        J Clin Oncol. 2003; 21: 690-696
        • Lone Z
        • Murthy PB
        • Zhang JH
        • Ericson KJ
        • Thomas L
        • Khanna A
        • et al.
        Comparison of renal function after open radical cystectomy, extracorporeal robot assisted radical cystectomy, and intracorporeal robot assisted radical cystectomy.
        Urol Oncol. 2021; 39: 301 e1- e9
        • Eisenberg MS
        • Thompson RH
        • Frank I
        • et al.
        Long-term renal function outcomes after radical cystectomy.
        J Urol. 2014; 191: 619-625
        • Huang CE
        • Yang YH
        • Chen WC
        • et al.
        Nephroureterectomy increase 5 year survival in patients on dialysis with upper urinary tract urothelial carcinoma.
        Oncotarget. 2017; 8: 79876-79883
        • Veeratterapillay R
        • Geraghty R
        • Pandian R
        • et al.
        Ten-year survival outcomes after radical nephroureterectomy with a risk-stratified approach using prior diagnostic ureteroscopy: a single-institution observational retrospective cohort study.
        BJU Int. 2022; 129: 744-751
        • Hashimoto T
        • Ohno Y
        • Nakashima J
        • et al.
        Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma.
        Jpn J Clin Oncol. 2015; 45: 1064-1068
        • Holton MR
        • Van Zijl PS
        • Oberle WT
        • Jacobs SC
        • Sklar GN.
        Complete urinary tract extirpation: the University of Maryland experience.
        Urology. 2006; 68: 65-69
        • Wu CF
        • Shee JJ
        • Ho DR
        • Chen WC
        • Chen CS.
        Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma.
        J Urol. 2004; 171: 126-129
        • Wolfe RA
        • Ashby VB
        • Milford EL
        • et al.
        Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.
        N Engl J Med. 1999; 341: 1725-1730
        • Kondo T
        • Hara I
        • Takagi T
        • et al.
        Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study.
        Int J Urol. 2014; 21: 453-459
        • Kondo T
        • Tanabe K.
        The role of lymph node dissection in the management of urothelial carcinoma of the upper urinary tract.
        Int J Clin Oncol. 2011; 16: 170-178